The effects of vitamin E on non-proliferative diabetic retinopathy in type 2 diabetes mellitus: Are they sustainable with 12 months of therapy

被引:7
|
作者
Ho, J-Ian [1 ]
Ng, En Yng [1 ]
Chiew, Yilynn [1 ]
Koay, Yan Yi [1 ]
Chuar, Pei Fen [1 ]
Phang, Sonia Chew Wen [1 ]
Ahmad, Badariah [1 ]
Kadir, Khalid Abdul [1 ]
机构
[1] Monash Univ Malaysia, Sch Med & Hlth Sci, Subang Jaya 46150, Selangor, Malaysia
来源
SAGE OPEN MEDICINE | 2022年 / 10卷
关键词
Type 2 diabetes mellitus; diabetic retinopathy; tocotrienol; vitamin E; anti-angiogenesis; anti-inflammatory; anti-oxidant; anti-thrombosis; retinal microhaemorrhages; diabetic macular oedema; serum vascular endothelial growth factor; ENDOTHELIAL GROWTH-FACTOR; PALM TOCOTRIENOLS; MACULAR EDEMA; CELLS; ANGIOGENESIS; PROGRESSION; VEGF;
D O I
10.1177/20503121221095324
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Prolonged uncontrolled hyperglycaemia has shown to cause oxidative stress, inflammation, thrombosis and upregulation of angiogenesis in diabetics, which all contributes to diabetic retinopathy development and progression. Vitamin E is found to have anti-inflammatory, anti-oxidative, anti-thrombogenic and anti-angiogenesis which could play an important role in early treatment of diabetic retinopathy. This study aims to investigate the effect of Tocotrienol-rich vitamin E (Tocovid) on the progression of retinal microhaemorrhages and diabetic macular oedema in patients with diabetic retinopathy. Method: This is a multi-centred, randomized, double-blinded, placebo-controlled trial which involved 55 eligible participants. The participants in the treatment group (n = 22) received Tocovid 200 mg twice daily while those in the placebo group (n = 23) would receive placebo twice daily. Both groups will be on the treatment for a total duration of 12 months. Both retinal signs will be assessed at baseline, 2 months, 6 months and 12 months of treatment to determine the progression of diabetic retinopathy. Serum vascular endothelial growth factor which reflects on the angiogenesis process in the eye was analysed as well at similar time points as the retinal findings. Results: After 12 months of treatment, the placebo group had a significant increase of 23.42% in retinal microhaemorrhages (p < 0.05), but the Tocovid group had no significant changes. Moreover, the Tocovid group showed a significant decrease of 48.38% in area of diabetic macular oedema over the 12 months period (p < 0.05), but the placebo group had no significant changes. Meanwhile, there was no significant difference in serum vascular endothelial growth factor level when comparing between both groups. Conclusion: These findings could indicate that Tocovid has an important role in preventing early diabetic retinopathy progression.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Vitamin B Intervention in Non-Proliferative Diabetic Retinopathy
    Smolek, Michael
    Notaroberto, Neil
    Pradillo, Lisa
    Jaramillo, Arley
    Lee, Kaci
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [2] Normal parathyroid hormone and non-proliferative diabetic retinopathy in patients with type 2 diabetes
    Sun, Shengnan
    Wang, Yahao
    Ma, Wenru
    Cheng, Bingfei
    Dong, Bingzi
    Zhao, Yuhang
    Hu, Jianxia
    Zhou, Yue
    Huang, Yajing
    Wei, Fanxiang
    Wang, Yangang
    JOURNAL OF DIABETES INVESTIGATION, 2021, 12 (07) : 1220 - 1227
  • [3] A study of the efficacy of alpha-lipoic acid in patients with type 2 diabetes mellitus and non-proliferative diabetic retinopathy
    Trakhtenberg, Y. A.
    Milen'kaya, T. M.
    Ametov, A. S.
    Demidova, T. Y.
    DIABETES MELLITUS, 2006, 9 (03): : 39 - 41
  • [4] Use of retinalamin at an early stage of treatment of non-proliferative diabetic retinopathy in children with type 1 diabetes mellitus
    Malysheva, N. A.
    Rossokhin, V. F.
    SOVREMENNYE TEHNOLOGII V MEDICINE, 2011, (03) : 160 - 162
  • [5] Treatment effects of captopril on non-proliferative diabetic retinopathy
    Wang Ning
    Zheng Zhi
    Jin Hui-yi
    Xu Xun
    CHINESE MEDICAL JOURNAL, 2012, 125 (02) : 287 - 292
  • [6] Treatment effects of captopril on non-proliferative diabetic retinopathy
    WANG Ning
    ZHENG Zhi
    JIN Hui-yi
    XU Xun
    中华医学杂志(英文版), 2012, (02) : 287 - 292
  • [7] Construction of a prediction model for non-proliferative retinopathy in type 2 diabetes
    Liu, Y.
    Wang, C.
    Qiao, J.
    Li, Y.
    Lv, D.
    Li, L.
    Wang, Y.
    DIABETOLOGIA, 2024, 67 : S436 - S436
  • [8] Association between serum lipoprotein (a) level and progression of non-proliferative diabetic retinopathy in Type 2 diabetes
    Funatsu, Hideharu
    Shimizu, Erika
    Noma, Hidetaka
    Mimura, Tatsuya
    Hori, Sadao
    ACTA OPHTHALMOLOGICA, 2009, 87 (05) : 501 - 505
  • [9] Association of macular pigment optical density with early stage of non-proliferative diabetic retinopathy in Chinese patients with type 2 diabetes mellitus
    She, Chong-Yang
    Gu, Hong
    Xu, Jun
    Yang, Xiu-Fen
    Ran, Xue-Tao
    Liu, Ning-Pu
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2016, 9 (10) : 1433 - 1438
  • [10] Sensomotor and psychomotor productivity in patients with diabetes mellitus and non-proliferative retinopathy
    Kurashvili, Ramaz B.
    Tsutskiridze, Lika R.
    Tsibadze, Alexandre D.
    Korkelia, Maka T.
    Kurashvili, Givi R.
    Tsibadze, David A.
    Shelestova, Elena L.
    Dundua, Mzia G.
    ENDOCRINE JOURNAL, 2010, 57 : S378 - S379